drugset / Trial / NCT00686868

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

NCT00686868

Phase 1 Completed 35 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptable safety profile.

Timeline

Start
2008-06-13
Primary completion
2011-03-11
Completion
2011-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 0.3 mg Subcutaneous
Subject Ofatumumab Monoclonal antibody 3 mg Subcutaneous
Subject Ofatumumab Monoclonal antibody 30 mg Subcutaneous
Subject Ofatumumab Monoclonal antibody 60 mg Subcutaneous
Subject Ofatumumab Monoclonal antibody 100 mg Subcutaneous

Indications